Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemoforce is a haematinic combination product developed and marketed by Shalina Healthcare, primarily targeting the African healthcare market. Formulated as a syrup, it contains a blend of essential nutrients required for the production and maturation of red blood cells, including iron (as ferric ammonium citrate, sodium feredetate, or haemoglobin), folic acid (vitamin B9), and cyanocobalamin (vitamin B12). Some variants are enriched with zinc sulphate and ascorbic acid (vitamin C) to enhance therapeutic efficacy and iron absorption. Hemoforce is indicated for the treatment of various anemias, such as iron-deficiency and hypochromic anemia, and is used to manage nutritional deficiencies associated with pregnancy, lactation, malaria, and post-hemorrhagic states.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hemoforce.